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ABSTRACT 
 
The link between Alzheimer’s disease and the M1 muscarinic receptor 
subtypes makes the latter a viable target for modulating the 
pathogenesis involved in the development of the disease. The aim of 
this project was to create a novel drug to modulate an in silico-created 
homology model of the M1 receptor to manage Alzheimer’s disease. 
The preliminary part of this study involved creation of a homology 
model of the M1 receptor. This was followed by analysis of the ligand-
binding pocket and in silico design of novel molecules capable of 
modulating this proposed structure. SYBYL-X®, X-SCORE®, 
LigBuilder®, Visual Molecular Dynamics (VMD), Accelrys® Draw, 
Accelrys® Discovery Studio 3.5 and the Protein Data Bank were used 
to generate the results. A homology model for the M1 receptor was 
created. Analysis of the ligand binding pocket resulted in 12 varying 
conformers; that with optimal binding affinity was chosen to create a 
seed. This generated 200 molecules, classified into 12 chemical 
families, 124 of which were retained due to conformity to Lipinski’s 
Rules. Highest & lowest-ranked molecules in each chemical family 
were structurally-analysed, which yielded chemical moieties 
responsible for optimal chemical binding to the proposed ligand 
binding pocket. The de novo molecules created and optimized present 
viable leads for high-throughput screening in subsequent drug-design 
studies, potentially leading to identification of novel M1 muscarinic 
receptor subtype modulators for the use in managing Alzheimer’s 
disease. 
Introduction: 
Alzheimer’s disease (AD) is the most commonly 
diagnosed form of dementia, affecting more than 35 million 
patientsglobally 1. The regions of the brain that are linked 
with specialised mental functionality - especially the 
neopallium, isocortex and hippocampus - are the most 
adversely affected by the distinctive progress of Alzheimer’s 
disease.  
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This includes extracellular accumulation of α-amyloid (from 
APP, amyloid precursor protein) in ageing plaques, 
intracellular arrangement of a neurofibrillary mesh containing 
an unusually phosphorylated form of a microtubule-
associated protein, tau (τ), as well as a reduction in number of 
pyramidal neurons and neuronal synapses.   
Drug therapy currently available on the market is 
symptomatic and does not treat the underlying cause of the 
disease. Patients still show signs of clinical and 
communicative deterioration irrespective of pharmacological 
therapy 2.   
The M1 mAChR subtype has long been known to 
be the most prevalent subtype found within the CNS and is 
associated with cognition in regions of the brain such as the 
striatum and hippocampus 3. The M1 and M3 mAChRs 
have been linked with one hypothesised pathology of AD 4. 
This correlation suggests that T-Proteins are released from 
cells as a reaction to neuronal disintegration, resulting in a 
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toxic effect on the surrounding cells through modulation of 
the M1 and M3 receptors. This prompts neuronal 
disintegration through a sustained increase in intracellular 
calcium levels 5. This association followed the theory that 
“M1 receptors are associated with muscarinic antagonist-
induced amnesia” 6.   
Continuation of this theory led to the proposal 
that an activated M1 mAChR enables bypassing of the 
causative amyloidogenic pathways, preventing production 
of Aβpeptides, deterring disease progression 7.  
The strong relationship between the M1 receptors 
and cognitive deficit, neuronal inflammation and 
mitochondrial dysfunction was emphasised, resulting in a 
new locus for drug targeting in AD 8. T-Phosphorylation 
was shown to be reduced when M1 stimulation was carried 
out, reducing one of the pathogeneses suggested for the 
disease9. Therefore, targeting the M1 muscarinic receptor is 
a viable therapeutic target for AD and other 
neurodegenerative disease 10. 
Research studies show that advances in the 
molecular pathogenesis of AD have led to new drug 
candidates with disease-modifying potential, which are 
currently within the testing phases of clinical trials11, while 
antineoplastic drugs administered to mice with AD 
symptoms show small but consistent signs of 
improvement12.  
 
Figure 1 Chemical Structure of Tiotropium Drawn in 
Accelrys® Draw version 4.1 
 
Tiotropium is a long-acting anticholinergic agent 
indicated in the treatment of chronic obstructive pulmonary 
disorder (COPD)13.  It is a potent muscarinic receptor 
antagonist through its high binding affinity and long 
dissociation time from M1 and M3 receptors, having an 
almost ten-fold increase in binding strength and potency 
when compared to ipratropium14.   
Two significant properties of tiotropium make it a 
suitable candidate for a drug design study – it is kinetically-
selective for the M1 mAChR and has a prolonged duration of 
action15. This implies that the structure-activity relationship 
(SAR) of the molecule is optimal to be studied and 
manipulated in order to achieve a novel drug with a 
favourable ligand binding profile.  
 
Methodology: 
Homology Modelling : 
X-ray crystallographic resolution of the human M1 
mAChR has to date not been achieved. The generation of a 
robust homology model was considered as vital in the context 
of a receptor-based rational design study. Homology 
modelling was, in this case, carried out using UCSF Chimera, 
following the premise that primary amino acid sequences  
result in similar three-dimensional configurations. 
 
Figure 2:  Homology Model of the M1 mAChR 
 
The isoform sequences of the M1, M2 and M3 mAChR 
subtypes16 were aligned in order to obtain a visual 
representation of the similarity proportions that existed 
within the receptor subtypes. The M3 receptor sequence 
was isolated as a suitable template for a homology model of 
the M1 receptor to be generated in silico. This was done 
through analysis of similar structures available on the 
Protein Data Bank, which revealed that the M3 receptor 
had the highest degree of amino acid homology. 
 
Identification of Ligand Binding Contacts: 
The amino acids within the ligand binding pocket 
(LBP) of the template generated were identified using UCSF 
Chimera. The same procedure was carried out for the 
template M3mAChR and the results compared. Differences 
within the ligand binding contacts of the two implied that the 
homology modelling process yielded a different structure 
than the original. Altered points within the LBP are loci 
which should be targeted in the context of a drug design 
study.  
 
Ligand Docking : 
In order to dock tiotropium into the target M1 
receptor LBP, bound conformations of the ligand were 
extracted from the M3 mAChR using SYBYL-X®. A 
Surflex-Dock preparation was carried out to generate 
multiple conformers of tiotropium which identified 18 
different three-dimensional conformations that the ligand was 
allowed to adopt within the fixed target LBP.   
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A protomol was generated from this data, (Ref. 
Figure 3) which represented the target receptor’s binding 
cavity to which future ligands would be aligned. Regions 
indicating hydrophobic and hydrophilic moieties in the LBP 
were used to manipulate the molecule in silico so as to further 
complement the binding process and lower the subsequent 
kinetic energy of the receptor-ligand complex.  
 
Figure 3: Protomol of Tiotropium Conformations within M1 
Muscarinic Receptor Binding Site 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
Energy (Kcal mol-1) and ligand-binding affinity 
(LBA; pKd) of each of the conformational isomers of 
tiotropium were plotted against conformer number. The 
conformer with the highest LBA value and the lowest energy 
values was chosen to be the most likely to yield a drug with 
the desirable characteristics. Drug 3 [ref. Graph 1] was 
selected, having a LBA pKd of 5.99 and an energy value of 
1300.3kcalmol-1.  
Table 1: LBA (pKd) of each tiotropium conformer to the M1 
model generated in silico; arranged in order of descending 
LBA. 
 
 
 
 
 
 
 
,
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tiotropium Conformer LBA 
(pKd) 
Tiotropium in M3 6.46 
Tiotropium in M1 6.14 
3 5.99 
5 5.98 
6 5.98 
7 5.98 
4 5.97 
2 5.96 
1 5.93 
8 5.93 
10 5.91 
11 5.89 
13 5.89 
12 5.86 
9 5.83 
14 5.76 
15 5.76 
17 5.74 
16 5.73 
18 5.54 
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Seed Creation  
Structure-activity relationship (SAR) analysis of 
tiotropium identified loci within its structure considered 
essential to activity 17. The “non-essential” parts of the 
molecule were considered redundant and replaceable by 
other efficient, high-affinity moieties.  
 
Figure 4 : Conformer 3 of Tiotropium 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A seed was created using SYBYL-X® maintaining 
the essential regions of the tiotropium and choosing 
structural features of the molecule which could be modified 
to create seeds. Specifically, the high-torsion ring circled in 
Figure 4 was earmarked for elimination and substitution with 
lower-energy moieties in an attempt not only to increase 
affinity, but also molecular stability. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Generated Seed 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Molecular editing was carried out in SYBYL-X®. 
The editing process included the computational removal of 
the redundant, not crucial to binding moieties from the 
optimal tiotropium conformation and the assignment of H.spc 
hydrogens at loci which were consequently pre-designated as 
growing sites. 
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Novel Analogue Series Creation: 
Novel molecular growth was carried out using 
LigBuilder v1.2. Through its Pocket module, the LBP of 
the M1 mAChR model was mapped, and a general 
pharmacophore proposed. The grow module of LigBuilder 
used this data in order to delineate the pharmacophoric 
space available for in silico de novo molecular growth. 
Finally, implementation of the process module resulted in 
generated data organisation. This meant that the molecular 
cohort generated by the grow module was organised into a 
molecular database that was segregated into structurally 
similar families, and ranked according to LBA (pKd). Other 
physicochemical data including LogP and molecular weight 
were included in the database. 
 
Analysis and Optimisation: 
The generated molecular cohort was assessed for 
Lipinski rule compliance on the basis that this is the 
recognised gold standard for predicting oral 
bioavailability18. All 76 non-Lipinski rule compliant 
molecules were eliminated from the designed cohort [Ref. 
Graph 2]. 
Each molecule was structurally analysed in 
comparison with the rest of the members of the chemical 
family in order to understand the difference in binding 
affinities found.  Molecules from each chemical family 
having the highest LBA were compared to those having 
lower LBA values, with a structure-activity relationship 
target in mind. Structural features in molecules with higher 
bindingaffinities which were not present in those with 
lower affinities imply a significance in the binding process 
to the ligand-binding site.  
 
Table 2: LBA (pKd) of highest-ranking molecule of each 
chemical family generated in silico. 
 
Analysis of the molecule with the highest binding 
affinity with the highest-ranking molecule from the 
chemical family which yielded the greatest number of 
Lipinski rule-compliant molecules indicated structural 
moieties which may be exploited in order to formulate a 
structure with optimal binding properties.This molecule 
incorporated the structural backbone desirable which 
yielded the greatest number of compliant molecules, with 
side-chain moieties necessary for high binding affinity. 
 
Figure 6:  Proposed Molecule 
 
 
 
Discussion: 
This study is valuable in creating a homology 
model of the human M1 muscarinic receptor, delineating a 
proposed 3D ligand binding pocket within which novel 
molecular growth could be sustained. The tiotropium scaffold 
proved viable in generating novel in silico high-affinity 
structures capable of modulating the M1 receptor. Bioassays 
are recommended as a subsequent step to further validate the 
hypotheses made throughout this study.  
 
Conclusion: 
De novo molecules created and optimized present 
viable leads for high-throughput screening in subsequent 
drug-design studies, leading to identification of novel M1 
muscarinic receptor subtype modulators for the use in 
managing Alzheimer’s disease.  
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